Actively Recruiting
PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy
Led by University Hospital, Brest · Updated on 2024-06-26
56
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The value of 4D body-to-whole dynamic acquisition in FDG PET / CT to differentiate progression / pseudo-progression during the first therapeutic assessment (PET1) of metastatic melanoma treated with immune checkpoint inhibitors (ICI)to predict the progression of the disease..
CONDITIONS
Official Title
PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient aged 18 years or older
- Diagnosed with metastatic melanoma
- Treated with anti-PD1 immunotherapy: Nivolumab, Pembrolizumab, or combination Ipilimumab-Nivolumab
- Provided informed consent and have no objection to participation
You will not qualify if you...
- Patients under 18 years old
- Pregnant or breastfeeding women
- Presence of other types of tumors besides metastatic melanoma
- Not eligible for the examination
- Refusal to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital University ff Brest
Brest, Finistere, France, 29200
Actively Recruiting
Research Team
R
Ronan ABGRAL, MD-PhD
CONTACT
K
Karim AMRANE, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here